Artgen Biotech Group (MOEX: ABIO) is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. The platform is designed to enhance the efficacy and safety of vaccines, extend the duration of the immune response, optimize antigen dosage, and reduce production costs.
The technological platform was developed by RBT (BioTechnology Developments), a subsidiary of the Artgen Biotech Group. Thanks to Artgen Biotech’s investment, RBT will gain control over a pilot production facility in Perm Krai, where it will produce the core component of the vaccine platform: an adjuvant in the form of virus-like particles manufactured using a patented technology based on betulin, an organic compound. Additionally, the facility will be used to refine quality control methods and production technologies for new vaccine formulations.
The total investment in the development of the production component of RBT’s platform, including funds from private investors and debt financing, will exceed RUB 80 million, of which RUB 30 million will be allocated as equity capital.
RBT is a resident of Skolkovo and Technopark Medtech. Its shares are available for trading on the Moscow Exchange’s Over-The-Counter (OTC) market under the ticker symbol RBTY.
With the support of its industrial partner, Artgen Biotech, and its ecosystem, RBT is advancing a platform for the development of effective vaccines based on surface antigens and a proprietary corpuscular adjuvant. Previously, this platform was used to develop a coronavirus vaccine (Betuvax-Cov-2), an influenza vaccine (TetraFluBET), and a pentavalent combination vaccine against both influenza and coronavirus, developed in collaboration with the Nacimbio pharmaceutical holding. RBT’s technological platform reduces vaccine reactogenicity and minimizes post-vaccination side effects while maintaining high levels of protective efficacy. The company’s pipeline also includes vaccine candidates targeting a wide range of acute respiratory viral infections (ARVI), human papillomavirus (HPV), and tuberculosis.